

OMTN, Volume 28

Supplemental information

MicroRNA-10a/b inhibit TGF- β /Smad-induced renal fibrosis by targeting TGF- β receptor 1 in diabetic kidney disease

Jinxiang Li, Shuling Yue, Jingwen Fang, Junling Zeng, Siqi Chen, Jianwei Tian, Sheng Nie, Xiaoting Liu, and Hanying Ding




Figure S1. Albumin and glucose increased in urine from DKD mice.

(A, B) Albumin to creatinine ratio (A) and glucose concentration (B) in urine from STZ-treated mice.

Data were expressed as means \pm SEM, n=6 for each group. Student's t test was used for the comparison of two groups. *p < 0.05, **p < 0.01.




Figure S2. High glucose induces TGFBR1 protein in a time- and dose-dependent manner *in vitro*.

(A-C) Representative images of western blot for TGFBR1 in podocytes treated with glucose for various hours at 26mM (A) or at various concentrations for 24 hours (B), and quantification data (C). Equivalent mannitol was used as osmotic control. (D, E) TGFBR1 mRNA was not altered in podocytes treated with glucose for indicated time (D) or concentration (E). (F-H) Representative images of western blot for TGFBR1 in tubular cells treated with glucose for various hours at 25mM (F) or at various concentrations for 24 hours (G), and quantification data (H). Equivalent mannitol was used as osmotic control. (I, J) TGFBR1 mRNA was not altered in tubular cells treated with glucose for indicated time (I) or concentration (J). Data were expressed as means \pm SEM. Student's t test was used for the comparison of two groups. ANOVA were used for comparison among multiple groups. *p < 0.05, **p < 0.01.




Figure S3. Efficiency of siRNA and miRNA transfection in podocytes and tubular cells.

(A) NLRP3 expression in podocytes and tubular cells treated with siRNA targeting NLRP3 (siNLRP3) or negative control (siNC). (B-E) Expression of miR-10a or 10b in podocytes (B, C) or tubular cells (D, E) co-transfected with siNLRP3 and miR-10a or 10b mimic or antisense. (F-I) Expression of miR-10a or 10b in podocytes (F, G) or tubular cells (H, I) transfected with miR-10a or 10b mimic or antisense. Data were expressed as means \pm SEM. Student's t test was used for the comparison of two groups. * $p < 0.05$, ** $p < 0.01$.




Figure S4. miR-10a/b suppress fibrosis dependent on TGFBR1, and are modulated by XRN2 in tubular cells.

(A, B) Relative Colla (A) and ColIV3 (B) mRNA expression in tubular cells transfected with miR-10a or 10b antisense, 25mM glucose incubation was used after TGFBR1 inhibitor treatment (TGFBR1 in).

(C, D) Western blot for TGFBR1, FN and α -SMA protein in tubular cells transfected with miR-10a or 10b antisense in the presence of TGFBR1 inhibitor (C), and quantification data (D), DMSO was used as dissolvant control.

(E, F) Western blot for XRN2, TGFBR1, and FN protein expression in tubular cells treated with high glucose for 24 hours (E), and quantification in data (F).

(G) Relative miR-10a/b expression in tubular cells treated with high glucose (HG), siRNA targeting XRN2 (siXRN2) was introduced to evaluates its function in miR-10a or 10b expression, and RNA sequence without binding site was used as control (siNC).

(H, I) Western blot for XRN2, TGFBR1, and FN protein expression in tubular cells treated with siRNA targeting XRN2 (siXRN2), 24 hours later, miR-10a or miR-10b

mimic was transfected into tubular cells. Data were expressed as means \pm SEM. Student's t test was used for the comparison of two groups. ANOVA were used for comparison among multiple groups. *p < 0.05, **p < 0.01.

Table S1.

Clinical data in patients with biopsy proven diabetic kidney disease (n=19).

Variables	
Male, n (%)	10 (52.6%)
Age at biopsy (year)	51.74±2.02
Systolic blood pressure (mmHg)	146.4±4.70
Diastolic blood pressure (mmHg)	84.79±3.13
Serum creatinine (µmol/L)	136.8±15.96
Serum Urea (mmol/L)	8.94±0.75
Serum albumin (g/L)	29.49±1.74
Fasting blood glucose (mmol/L)	7.96±0.68
Estimated glomerular filtration rate ml/ min/ 1.73m ²	45.02±4.24
Urinary protein excretion (g/24h)	3.73±0.57